Regenicin IncOver The Counter Market:RGIN
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regenicin Inc | 15.4K | 0.0x | --- |
Evolutionary Genomics Inc | 5.3K | 0.0x | --- |
Evelo Biosciences Inc | 28.4K | 0.0x | --- |
Scopus Biopharma Inc | 12.6K | 0.0x | --- |
Miravant Medical Technologies | 40.0 | 0.0x | --- |
ARYx Therapeutics Inc | 30.0 | 0.0x | --- |
Company Information
Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.
Contact Information
- Headquarters
- 10530 Discovery DrLAS VEGAS, NV, United States 07424
- Phone
- 646-403-3581
- Fax
- ---
Executives
- Chief Executive Officer, Director
- Randall McCoy
- Chief Financial Officer, Director
- John Weber
- Chief Science Officer
- J. Roy Nelson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.4K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 153.5M |
Regenicin Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.01 |
Book Value | $-0.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
